Abstract 4937: Immunoproteasome inhibitors for the treatment of t(4;11)-driven ALL
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4937
Abstract: The t(4;11)(q21;q23) chromosomal translocation that creates the MLL-AF4 fusion protein, confers a poor prognosis in infant acute lymphoblastic leukemia (ALL). This translocation also sensitizes cells to proteasome inhibitors bortezomib and carfilzomib, which are approved by… read more here.
Keywords: abstract 4937; mll af4; treatment driven; inhibitors treatment ... See more keywords